Survodutide

Survodutide

Survodutide is a synthetic dual agonist peptide targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It represents a next-generation approach to metabolic research beyond single-receptor GLP-1 agonism, combining the complementary metabolic actions of glucagon and GLP-1 signalling pathways. Survodutide has attracted significant preclinical and clinical research interest for its potential effects on energy expenditure, hepatic lipid metabolism, and body weight regulation.

Mechanism of Action

Survodutide co-activates GLP-1R and GCGR, both G-protein-coupled receptors that signal through cAMP elevation. GLP-1R activation enhances glucose-dependent insulin secretion and suppresses appetite via central and peripheral mechanisms, while GCGR activation stimulates hepatic glucose output, promotes lipolysis, and increases energy expenditure through thermogenic pathways. The dual agonism is hypothesised to produce additive or synergistic effects on fat oxidation and weight reduction, making survodutide a valuable tool for studying GCGR/GLP-1R crosstalk and metabolic regulation.

Research Applications

• Dual GCGR/GLP-1R pharmacology and receptor crosstalk studies
• Hepatic lipid metabolism and non-alcoholic fatty liver disease (NAFLD) models
• Energy expenditure and thermogenesis research
• Obesity and body composition preclinical investigation
• Insulin secretion and glucose homeostasis modelling

Specifications

• Molecular Formula:  C₁₉₂H₂₈₉N₄₇O₆₁
• Molecular Weight: 4231.69 g/mol
• CAS Number: 2805997-46-8
• Purity: ≥98%
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.